The report on " Prostate Cancer Market by Diagnostic Techniques (Digital Rectal Exam (DRE) and Prostate Specific Antigen Test (PSA)), by Surgery (Radical Prostatectomy, Orchidectomy and Trans Urethral Resection (TUR)), by Radiation Therapy (External Beam Radiation Therapy (3D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Stereotactic Body Radiation Therapy and Proton Beam Radiation Therapy) and Brachytherapy (Permanent Brachytherapy and Temporary Brachytherapy)), by Chemotherapy (Docetaxel, Etoposide, Vinblastine, Carboplatin and Vinorelbine), and by Region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)", is published by Market Data Forecast. The Global Prostate Cancer Market was priced $48 billion in 2016 and calculable to be growing at a CAGR of 9.5% to achieve $75.56 billion by 2021, within the mentioned forecast period. The cancer cells may spread from the prostate to the parts of the body, through the bones and humor nodes. In later stages of cancer, it can cause difficulty in urination, blood in the piss, etc. Old age, family history and race are a number of the factors that increase the chance of prostate cancer. Prostate cancer is most of the times diagnosed by diagnostic test. The prostate cancer market contains a high demand for original medicine that focuses on unmet desires like less toxicity, higher progression free survival, lesser price, improved effectiveness, and improved survival time.